Novartis

News

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalospor

News

UK patient group warns COVID could limit access to Novartis'...

NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales - but a patient group warned that access could be limited until the pan

News

CHMP clears way for EU approval of Novartis' MS drug

Novartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, paving the way for a likely approval in the coming weeks.

News

Novartis hails digital strategy as profits hold up during pa...

Novartis has said that its investment in digital technology has helped it to ride out the worst of the pandemic, although sales of some of its newly-launched products have been affected by

News

Roche targets wet AMD with faricimab and its 16-week regimen

Twin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, as the company’s challenge to rivals from Novartis and Baye

News

Sobi gets EU nod for Doptelet in rare blood disorder ITP

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the company expects to accelerate sales of the drug.

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

UK patient group warns COVID could limit access to Novartis'...

CHMP clears way for EU approval of Novartis' MS drug

Novartis hails digital strategy as profits hold up during pa...

Roche targets wet AMD with faricimab and its 16-week regimen

Sobi gets EU nod for Doptelet in rare blood disorder ITP

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks